Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Product/Service

CORRECTING and REPLACING Fujirebio Diagnostics Receives FDA Breakthrough Device Designation for Lumipulse® G ?-Amyloid Ratio (1-42/1-40) Quantitative In Vitro Diagnostic Test

The date in the first paragraph, first sentence of release should read: February 1, 2019 (instead of January 3, 2019). The website in the fifth paragraph, last sentence should read www.alz.org (instead of ww.alz.org).

The corrected release reads:


Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings Inc., has received Breakthrough Device Designation (formerly known as Expedited Access Pathway (EAP) designation) from the Center of Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) on February 1, 2019 for the Lumipulse G ?-Amyloid Ratio (1-42/1-40) quantitative in vitro diagnostic test. The Breakthrough Devices Program is designed to expedite the development and review of certain medical devices that provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition.

"We are very pleased that the FDA has granted us breakthrough status for this important new diagnostic tool in the fight against Alzheimer's Disease," said Monte Wiltse, President and CEO of Fujirebio Diagnostics, Inc. "The entire Fujirebio group of companies are committed to bringing novel diagnostic tools for Alzheimer's Disease to healthcare systems globally, and we look forward to working closely with the FDA to provide both physicians and patients this innovative, new test."

The Lumipulse G ?-Amyloid Ratio (1-42/1-40) is a quantitative in vitro diagnostic test using measurable ?-Amyloid 1-42 and ?-Amyloid 1-40 concentrations found in human cerebral spinal fluid (CSF) and combines those concentrations into a numerical ratio of ?-Amyloid 1-42/ ?-Amyloid 1-40 to estimate the presence of ?-Amyloid neuritic plaque pathology in the brain.

The Lumipulse G ?-Amyloid Ratio (1-42/1-40) combines the results of Lumipulse G ?-Amyloid 1-42 and ?-Amyloid 1-40 using the Lumipulse G System. The Lumipulse G ?-Amyloid Ratio (1-42/1-40) results are intended to aid in the assessment of adult patients, aged 50 years and over, presenting with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. The Lumipulse G ?-Amyloid Ratio (1-42/1-40) results must be interpreted in conjunction with other diagnostic tools such as neurological examination, neurobehavioral tests, imaging and routine laboratory tests.

A negative Lumipulse G ?-Amyloid Ratio (1-42/1-40) result is consistent with a negative amyloid PET scan result. A positive Lumipulse G ?-Amyloid Ratio (1-42/1-40) result is consistent with a positive amyloid PET scan result. A positive result does not establish a diagnosis of AD or other cognitive disorder. This test is not intended as a screening or stand-alone diagnostic assay. Fujirebio Diagnostics, Inc., looks forward to providing a commercially available in vitro diagnostic test to help in the assessment of Alzheimer's Disease; a disease with 5.7 million afflicted Americans resulting in the sixth leading cause of death in the United States (www.alz.org).

About Fujirebio Diagnostics, Inc.

Fujirebio Diagnostics is a global leader in the field of high quality in vitro diagnostics (IVD) testing. It has more than 40 years' accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products. Fujirebio Diagnostics has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions. For more information about Fujirebio Diagnostics, please call +1 610-240-3800 or visit us as www.fujirebio-us.com.

Fujirebio Diagnostics is today a member of Miraca Group (Miraca Holdings Inc. listed on the Tokyo Stock Exchange ? TYO: 4544).

These press releases may also interest you

at 08:29
Sitecore®, a global leader in digital experience management software, today announced the mid-year releases of Sitecore® Experience PlatformTM and Sitecore Content HubTM, delivering new features and product upgrades enabling marketers to more easily...

at 08:29
New Parks Associates research finds 13% of heads of US broadband households ages 65 and older consider the ability to interact with an independent living system using voice controls as a must-have feature. By comparison, 30% of current caregivers...

at 08:29
Sitecore®, the global leader in digital experience management software, today announced the launch of Sitecore® Content Marketing Platform (CMP). The stand-alone technology will improve the efficiency of marketers by merging strategic and project...

at 08:28
The Trendlines Group Ltd. ("Trendlines") (SGX: 42T)  today announced that it has signed a Subscription Agreement with Librae Holdings Limited ("LH"), for an SGD10.88 million (USD8 million) investment. London-based discretionary beneficiary to the...

at 08:20
Thunderhead, the global leader in Customer Engagement and Journey Orchestration technology is today announcing a strategic partnership with leading customer experience agency Proximity London. Supported by its proprietary Connected Creativity...

at 08:15
Information Builders, a leader in business intelligence (BI), analytics, and data management solutions, has announced the appointment of Bill Harmer as senior vice president (SVP) for Europe, Middle East, and Africa (EMEA). Reporting to the board of...

News published on 14 february 2019 at 11:15 and distributed by: